Cholesteryl ester transfer protein inhibitors for dyslipidemia: Focus on dalcetrapib

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 251-259

  Hegele, Robert A ^a   Alyse, S Goldberg ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Cardiovascular disease; CETP inhibitor; Dalcetrapib; HDL

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; TORCETRAPIB; TRIACYLGLYCEROL;

ALCOHOL CONSUMPTION; ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORTICOSTERONE BLOOD LEVEL; DIET RESTRICTION; DOSE RESPONSE; DRUG COMPETITION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; MESENTERY LYMPH NODE; NONHUMAN; PROTEIN FUNCTION; QT INTERVAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; CHOLESTEROL ESTER TRANSFER PROTEINS; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS, HDL; OXAZOLIDINONES; SULFHYDRYL COMPOUNDS;

EID: 84872320164     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S34976     Document Type: Review

References (67)

1. Baigent C, Keech A, Kearney P, Al E. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
2. Gordon T, Castelli W P, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med. 1977;62(5):707-714.
3. Gordon DJ, Probstfeld JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8-15.
4. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov. 2008;7(2):143-155.
5. Asztalos B F, Roheim PS, Milani RL, et al. Distribution of ApoA-I- containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20(12):2670-2676.
6. Rye K-A, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res. 2009; 50 Suppl:S195-S200.
7. Tabet F, Rye K-A. High-density lipoproteins, infammation and oxidative stress. Clin Sci. 2009;116(2):87-98.
8. Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ. On- and off- target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs. 2012;72(4):491-507.
9. Matsuura F. HDL from CETP-defcient subjects shows enhanced ability to promote cholesterol effux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest. 2006;116(5):1435-1442.
10. Asztalos BF, Collins D, Horvath K V, Bloomfeld HE, Robins SJ, Schaefer EJ. Relation of gemfbrozil treatment and high-density lipoprotein subpopulation profle with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metab Clin Exp. 2008;57(1):77-83.
11. Ballantyne FC, Clark RS, Simpson HS, Ballantyne D. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metab Clin Exp. 1982;31(5):433-437.
12. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci U S A. 1983;80(5):1449-1453.
13. Cheung V, Hegele RA. CETP Inhibitors: will they live up to their promise? Curr Cardiovasc Risk Rep. 2011;6(1):4-11.
14. Asztalos B F, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25(10):2185-2191.
15. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profle and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24(11):2181-2187.
16. Khera AV, Cuchel M, la Llera-Moya M de, et al. Cholesterol effux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135.
17. Doggrell SA. Dalcetrapib - restoring belief in modulating CETP as a benefcial mechanism in cardiovascular disease. Expert Opin Investig Drugs. 2012;21(4):569-573.
18. AIM-HIGH Investigators, Boden WE, Probstfeld JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267.
19. Gurfinkel R, Joy TR. Anacetrapib: hope for CETP inhibitors? Cardiovasc Ther. 2011;29(5):327-339.
20. HPS2-THRIVE [webpage on the Internet]. Oxford: Clinical Trial Service Unit [updated June 14, 2012]. Available from: http://www.ctsu.ox.ac.uk/~thrive/. Accessed June 18, 2011.
21. Niesor EJ. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol. 2011;22(4):288-295.
22. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116(12):3090-3100.
23. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007;48(6): 1263-1272.
24. Clark RW, Sutfn TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24(3):490-497.
25. McKenney JM, Davidson MH, Shear CL, Revkin JH. Effcacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoproteincholesterol levels on a background of at orvastatin. J Am Coll Cardiol. 2006;48(9):1782-1790.
26. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27(2):257-260.
27. Mullard A. Learning lessons from Pfzer's $800 million failure. Nat Rev Drug Discov. 2011;10(3):163-164.
28. Barter PJ, Caulfeld M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21): 2109-2122.
29. Nissen SE, Tardif J-C, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13): 1304-1316.
30. Kastelein JJP, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356(16):1620-1630.
31. Bots ML, Visseren FL, Evans G W, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582): 153-160.
32. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif J-C, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118(24):2506-2514.
33. Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 2009;150(5):2211-2219.
34. Forrest MJ, Bloomfeld D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154(7):1465-1473.
35. Miyares MA. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Ann Pharmacother. 2011;45(1):84-94.
36. Cannon C P, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406-2415.
37. Bloomfeld D, Carlson GL, Sapre A, et al. Effcacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(2):352-360. e2.
38. Krishna R, Garg A, Jin B, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;67(5):520-526.
39. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370(9603):1907-1914.
40. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther. 2008;84(6):679-683.
41. Hermann F, Enseleit F, Spieker LE, et al. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb Res. 2009;123(3):460-465.
42. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306(19):2099-2109.
43. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350(15):1505-1515.
44. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains effcient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51(12): 3443-3454.
45. Stein EA, Stroes ESG, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol. 2009;104(1):82-91.
46. Kobayashi J, Okamoto H, Otabe M, Bujo H, Saito Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis. 2002;162(1):131-135.
47. Stroes E, Kastelein J, Bénardeau A, et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angio- tensin-aldosterone system in rats. Br J Pharmacol. 2009;158(7): 1763-1770.
48. Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J. 2010;31(4):480-488.
49. Derks M, Abt M, Mwangi A, Meneses-Lorente G. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. Eur J Clin Pharmacol. 2010;66(8):775-783.
50. Derks M, Anzures-Cabrera J, Turnbull L, Phelan M. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, Phase I study. 2011;31(5):325-335.
51. Derks M, Abt M, Phelan M, et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol. 2010;50(10):1188-1201.
52. Derks M, Abt M, Phelan M. Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe. Br J Clin Pharmacol. 2010;70(6):825-833.
53. Derks M, Fowler S, Kuhlmann O. A single-center, open-label, one- sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther. 2009;31(3):586-599.
54. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Effcacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105(18):2159-2165.
55. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95(9):1085-1088.
56. Fayad ZA, Mani V, Woodward M, et al. Safety and effcacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011; 378(9802):1547-1559.
57. Luscher T F, Taddei S, Kaski JC, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VES- SEL randomized clinical trial. Eur Heart J. 2012;33(7):857-865.
58. Roche. A study of the effect of dalcetrapib on artherosclerotic disease in patients with coronary artery disease. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated August 15, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01059682.NLM identifer: NCT01059682. Accessed September 9, 2012.
59. Roche. A study of dalcetrapib in patients hospitalized for an acute coronary syndrome (Dal-ACUTE) In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated July 5, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01323153.NLM identifer: NCT01323153. Accessed September 3, 2012.
60. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: effcacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158(6): 896-901. e3.
61. Robinson JG. Dalcetrapib: a review of Phase II data. Expert Opin Investig Drugs. 2010;19(6):795-805.
62. F Hoffmann-La Roche Ltd. Roche provides update on Phase III study of dalcetrapib [media release]. Basel: F Hoffmann-La Roche Ltd; 2012 [May 7]. Available from: http://www.roche.com/media/media_releases/ med-cor-2012-05-07.htm. Accessed. June 11, 2012.
63. Miller R. Roche stops dalcetrapib trial for lack of beneft. Montreal: theheart.org; 2012. Available from: http://www.theheart.org/arti-cle/1395141.do. Accessed May 30, 2012.
64. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777-2788.
65. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580.
66. Nicholls SJ. Evacetrapib. Curr Cardiol Rep. 2012;14(3):245-250.
67. Harikrishnan LS, Finlay HJ, Qiao JX, et al. Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) Inhibitors. J Med Chem. 2012;55(13):6162-6175.